When Will Wegovy Be Available on the NHS — and What Are Your Options Now?

What NICE said, and what that means in practice

NICE published its recommendation for Wegovy in March 2023. On paper, that sounds like a green light. In practice, the guidance comes with conditions that significantly limit who qualifies and where treatment is delivered.

Under TA875, Wegovy is recommended for adults with a BMI of 35 or above who also have at least one weight-related condition (such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea) and only when treatment is delivered within a specialist weight management service with multidisciplinary support. BMI thresholds are 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Treatment is approved for a maximum of two years, and NICE advises stopping if someone has not lost at least 5% of their body weight after six months on the maintenance dose.

Those conditions mean a GP cannot simply write a Wegovy prescription. The patient must be referred into a specialist tier of service, and those services have their own waiting lists. NHS England's guidance on weight management injections is clear that meeting the criteria does not guarantee timely access. If you are wondering when Wegovy will realistically become available on the NHS, the honest answer depends on where you live and how quickly local services are expanding, because in some areas, people wait well over a year.

The real decision: NHS queue or a private clinical route

For most people asking this question, the practical issue is not whether Wegovy is theoretically available, it is how long the wait might be and whether there is a legitimate alternative.

There is. Adults who meet the clinical eligibility criteria for semaglutide can access a private prescription through a GPhC-registered pharmacy without joining an NHS waiting list or needing a specialist referral. Whether Wegovy is available to you on the NHS depends on your BMI, your existing conditions, and the services in your area. Private prescription services assess the same clinical picture, they just do so independently, and without the queue.

That said, private treatment is not suitable for everyone and is not free. A clinically thorough process still applies: identity checks, weight verification, a full medical history, and a prescriber's assessment before any medicine is dispensed. The question to ask yourself is whether the wait for NHS access is realistic given your health, or whether acting sooner through a regulated private route makes sense for you. Our Wegovy overview covers what the treatment involves if you are still weighing that up.

Scotland, Wales and Northern Ireland, access differs

NHS access to Wegovy is not uniform across the UK. NICE guidance applies in England; Scotland, Wales and Northern Ireland each commission weight management medicines differently. In Scotland, criteria and thresholds are set by NHS Scotland and can vary from those in TA875. If you are based outside England, the position in Scotland is worth reading separately, and checking with your GP about your local pathway is always the most reliable starting point.

One thing common to all four nations: Wegovy remains a prescription-only medicine everywhere in the UK. Buying it through any channel that does not involve a prescriber assessment is not legal, and the MHRA has warned about the risks of counterfeit pens sold online. Worth checking any pharmacy you consider against the GPhC register before you share personal or medical information.

What comes next on the NHS, and what to do while you wait

The NHS rollout of weight management medicines is expanding. Tirzepatide (Mounjaro) received a NICE recommendation in December 2024 and is being phased into primary care from 2025 onwards, which may ease some of the pressure on specialist services, though Wegovy and tirzepatide are separate pathways. If you are currently on an NHS waiting list, keeping in touch with your GP is the most useful thing you can do; your situation can change, and so can local commissioning.

If the wait is affecting your health now, a private consultation is worth considering. Whether semaglutide is accessible through the NHS for weight loss is a question our prescribers hear regularly. There is no pressure to decide immediately, but if you do want to explore the private route, a consultation with a clinician is the right first step, not a purchase. You can look at what Wegovy costs privately to understand the financial picture before deciding. When you are ready, starting a free consultation takes a few minutes and is reviewed the same day by a GPhC-registered prescriber.